- Home
- STG vs ADVM Comparison
STG vs ADVM Comparison
Compare STG & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- ADVM
- Stock Information
- Founded
- STG 2003
- ADVM 2006
- Country
- STG China
- ADVM United States
- Employees
- STG N/A
- ADVM N/A
- Industry
- STG Other Consumer Services
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STG Real Estate
- ADVM Health Care
- Exchange
- STG Nasdaq
- ADVM Nasdaq
- Market Cap
- STG 112.4M
- ADVM 94.6M
- IPO Year
- STG 2018
- ADVM 2014
- Fundamental
- Price
- STG $5.66
- ADVM $4.31
- Analyst Decision
- STG
- ADVM Buy
- Analyst Count
- STG 0
- ADVM 5
- Target Price
- STG N/A
- ADVM $16.60
- AVG Volume (30 Days)
- STG 2.6K
- ADVM 1.0M
- Earning Date
- STG 11-20-2025
- ADVM 11-07-2025
- Dividend Yield
- STG N/A
- ADVM N/A
- EPS Growth
- STG N/A
- ADVM N/A
- EPS
- STG 3.59
- ADVM N/A
- Revenue
- STG $279,374,215.00
- ADVM $1,000,000.00
- Revenue This Year
- STG N/A
- ADVM $1,191.10
- Revenue Next Year
- STG N/A
- ADVM N/A
- P/E Ratio
- STG $1.57
- ADVM N/A
- Revenue Growth
- STG N/A
- ADVM N/A
- 52 Week Low
- STG $4.28
- ADVM $1.78
- 52 Week High
- STG $15.00
- ADVM $8.18
- Technical
- Relative Strength Index (RSI)
- STG 25.52
- ADVM 50.55
- Support Level
- STG $6.20
- ADVM $4.18
- Resistance Level
- STG $6.98
- ADVM $4.37
- Average True Range (ATR)
- STG 0.17
- ADVM 0.20
- MACD
- STG -0.07
- ADVM -0.03
- Stochastic Oscillator
- STG 13.07
- ADVM 51.58
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.